INSTITUTE OF IMMUNOLOGY AND GENETICS

Institute of Immunology and Genetics, Pfaffplatz 10, 67655 Kaiserslautern

LABORATORY MEDICINE
Dr. med. Bernhard Thiele
Prof. Dr. med. Jens Verheyen

HUMAN GENETICS
Prof. Dr. med. Wolfram Henn
Dr. med. Anne-Karin Kahlert

Phone: +49(0)631/31670-0 Fax: +49(0)631/31670-20
office@immungenetik-kl.de | www.immungenetik-kl.de

Requesting physician:	**Patient information:**

Request Form Familial Tumor Predispositions

Cause of examination: ☐ diagnostic ☐ predictive for familial mutation _____

Clinical information:

Family history:

☐ Patient clinically affected

☐ No previous molecular genetic examinations existent

☐ The following previous molecular genetic examinations have been done:

_____

Date / Time of sampling:	**Signature:**

Specimen requirements and logistics:

- **Patient Consent Form for Genetic Testing according to the German Law and Request Form**
- **Billing information (Insurance-, Institutional- or Selfpay-Billing)**
- **5 ml EDTA blood collection tube labeled with patient name and date of birth**

Patient name: _____ **DOB:** _____

Therapy-relevant diagnostics of BRCA1/BRCA2

☐ Testing before using a PARP inhibitor
(genetic counselling is not required before testing)
(Indication: advanced ovarian carcinoma, metastatic and HER2-negative breast carcinoma, metastatic pancreatic carcinoma after platinum-based chemotherapy, metastatic castration-resistant prostate carcinoma)

☐ **Hereditary Breast-/Ovarian Cancer (HBOC)**
Step 1: *BRCA1, BRCA2, CHEK2, PALB2, RAD51C*
Step 2: *ATM, BRIP1, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, RAD51D, STK11, TP53*

☐ **Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch-Syndrom**
after pos. MSI or reduction of expression

- ☐ *MSH2, MSH6*
- ☐ *MLH1, PMS2*

If Amsterdam II criteria are met:

- ☐ Step 1: *MLH1, MSH2, MSH6, PMS2*
  Step 2: *EPCAM*

☐ **Familial adenomatous Polyposis (FAP)**
APC

☐ **MUTYH- associated Polyposis (MAP)**
MUTYH

☐ **Polymerase proofreading-associated Polyposis (PPAP)**
POLD1, POLE

☐ **Panel-Analysis of Polyposis coli**
APC, MUTYH, POLD1, POLE

☐ **Familial juvenile Polyposis Syndrome**
BMPR1A, SMAD4

☐ **Peutz-Jeghers-Syndrome**
STK11

☐ **Cowden-Syndrome**
PTEN

☐ **Diffuse type gastric cancer**
CDH1

☐ **Familial gastric cancer**
BMPR1A, BRCA2, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, PMS2, STK11, TP53

☐ **Familial pancreatic cancer**
Step 1: *BRCA1, BRCA2, CDKN2A, CHEK2, PALB2, STK11*
Step 2: *APC, ATM, BMPR1A, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SMAD4, TP53, VHL*

☐ **Li Fraumeni-Syndrome**
TP53, CHEK2

☐ **Multiple endocrine Neoplasia type 1 (MEN1)**
MEN1

☐ **Multiple endocrine Neoplasia type 2 (MEN2)**
RET

☐ **Von Hippel-Lindau-Syndrome**
VHL

☐ **Fanconi-Anemia**
Step 1: *FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL*
Step 2: *BRCA1, BRCA2, BRIP1, FANCM, PALB2, RAD51C, SLX4*

☐ **Wilms Tumor**
WT1

☐ **Familial renal cell carcinoma**
BAP1, CDKN1C, CHEK2, DICER1, DIS3L2, EPCAM, FH, FLCN, GPC3, HNF1A, MET, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, SDHA, SDHAF2, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL, WT1

☐ **Hereditary Paraganglioma- Pheochromocytoma Syndrome**
BAP1, FH, KIF1B, MAX, MEN1, NF1, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL